<?xml version="1.0" encoding="UTF-8"?>
<p id="Par41">The renin–angiotensin–aldosterone system (RAAS) inhibitors, ACEi and ARB, confer potent dual effects, not only as cardiovascular protective therapies but also as anti-inflammatory and immunomodulatory agents [
 <xref ref-type="bibr" rid="CR119">119</xref>]. ACE2, the enzyme that converts angiotensin (Ang) I to Ang II, is expressed near the surface of human epithelial cells throughout the body, including the lungs [
 <xref ref-type="bibr" rid="CR120">120</xref>]. ACE2 receptors are the human cell entry points for SARS-CoV-2 [
 <xref ref-type="bibr" rid="CR120">120</xref>]. It was shown with SAR-CoV-1 that binding to ACE2 led to its downregulation and increased Ang II [
 <xref ref-type="bibr" rid="CR120">120</xref>]. There is a theoretical risk that ACEIs and ARBs can increase SARS-CoV-2 attachment by upregulating ACE2 [
 <xref ref-type="bibr" rid="CR121">121</xref>], although this was not substantiated by any human data and is an urgent research priority.
</p>
